Speaker

Prof. Dr. Jan de Hoon

Presentation title

Biomarkers: what’s in a name?

Presentation outline

A short introduction will be given on a mini-symposium focusing on imaging techniques as biomarkers in early clinical drug development. What are biomarkers? What is their added value to clinical drug development in general and to exploratory clinical trials in particular?

Job title

Head of the Center for Clinical Pharmacology (KULeuven/UZ Leuven) / Chairman Belgian Association of Phase I Units (BAPU)

Biography

After obtaining a Master in Chemical Sciences Jan de Hoon was trained as a MD and specialised in General Internal Medicine. He is a certified Clinical Pharmacologist and has a PhD in Medical Sciences.

Jan has over 15 years of experience in clinical pharmacology, partly in industry, partly in academia. He has a special interest in early clinical drug development including exploratory clinical trials, first-in-man, imaging and biomarker studies.

He is chairman of the Belgian Association of Phase I Units (BAPU) of which he was one of the founding members. He is Fellow of the Belgian College of Pharmaceutical Medicine (BCPM) and member of the Belgian Association of Pharmaceutical Physicians (BeAPP). At an international level he is member of the British Pharmacological Society, Council member for Belgium within the European Association for Clinical Pharmacology and Therapeutics (EACPT) and board member of the Dutch Society for Clinical Pharmacology and Biopharmacy.

At present, he is appointed as Full Professor in Pharmacology/Clinical Pharmacology at the university of Leuven (KULeuven). He is head of the Center for Clinical Pharmacology located in the University Hospitals of Leuven.

List of publications

Koen Van Laere, Guy Bormans, Sandra M. Sanabria-Bohorquez, Tjibbe de Groot, Patrick Dupont, Inge De Lepeleire, Jan de Hoon, Luc Mortelmans, Richard J. Hargreaves, John R. Atack, and H. Donald Burns. In Vivo Characterization and Dynamic Receptor Occupancy Imaging of TPA023B, an α2/ α3/ α5 Subtype Selective ү-Aminobutyric Acid-A Partial Agonist. Biol Psychiatry 2008 Jul 15;64(2):153-61.

Van Laere K., Goffin K, Casteels C, Dupont P, Mortelmans L, de Hoon J, Bormans G. Gender-dependent increase with healthy aging of the human cerebral cannabionoid-type 1 receptor binding using [18F]MK-9470 PET. Neuroimage 2008; 39(4): 1533-41.

Koen Van Laere, Karolien Goffin, Cindy Casteels, Luc Mortelmans, Jan de Hoon, Igor Grachev, Mathieu Vandenbulcke, Guido Pieters. Relationship of Type 1 Cannabinoid Receptor Availability in the Human Brain to Novelty-Seeking Temperament. Arch. Gen. Psychiatry 2009; Vol. 66 (2): 196-204.

JR Atack, KA Wafford, LJ Street, GR Dawson, S Tye, K Van Laere, G Bormans, SM Sanabria-Bohórquez, I De Lepeleire, JN de Hoon, A Van Hecken, HD Burns, RM McKernan, MG Murphy and RJ Hargreaves. MRK-409 (MK-0343), A GABAA Receptor Subtype-Selective Agonist, is a Non-sedating Anxiolytic in Preclinical Species but Causes Sedation in Man. J Psychopharmacol 2010; 25(3):314-328.

JR Atack, DJ Hallett, S Tye, KA Wafford, C Ryan, SM Sanabria-Bohórquez, Wai-si Eng, RE Gibson, HD Burns, GR Dawson, RW Carling, LJ Street, A Pike, I De Lepeleire, K Van Laere, G Bormans, JN de Hoon, A Van Hecken, RM McKernan, MG Murphy and RJ Hargreaves. Preclinical and clinical pharmacology of TPA023B, A GABAA Receptor α2/α3 Subtype-Selective Agonist. J Psychopharmacol 2010; 25(3): 329-344.

Mark E. Schmidt, Randolph D. Andrews, Peter van der Ark, Terry Brown, Erik Mannaert, Thomas Steckler, Jan de Hoon, Koen Van Laere. Dose-dependent effects of the CRF1 receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology 2010; 208:109-119.

Bart Van der Schueren, Koen Van Laere, Nathalie Gérard, Guy Bormans, Jan de Hoon et al. Interictal Type 1 Cannabinoid Receptor Binding Is Increased in Female Migraine Patients. Headache (in press).